FDA Determines Regulatory Review Period for Trileptal Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Trileptal, a prescription medication, in response to a patent extension application submitted to the US Patent and Trademark Office (USPTO).